The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Abstract
Purpose: There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety of apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed. Patients and Methods: This was a randomized, double-blind, placebo-controlled phase III trial. Patients from 32 centers in China with advanced gastric or gastroesophageal junction adenocarcinoma, for whom two or more prior lines of chemotherapy had failed, were enrolled. Patients were randomly assigned to oral apatinib 850 mg or placebo once daily. The primary end points were overall (OS) and progression-free survival (PFS). Results: Between January 2011 and November 2012, 267 patients were enrolled. Median OS was significantly improved in the apatinib group compared with the placebo group (6.5 months; 95% CI, 4.8 to 7.6 v 4.7 months; 95% CI, 3.6 to 5.4; P = .0149; hazard ratio, 0.709; 95% CI, 0.537 to 0.937; P = .0156). Similarly, apatinib significantly prolonged median PFS compared with placebo (2.6 months; 95% CI, 2.0 to 2.9 v 1.8 months; 95% CI, 1.4 to 1.9; P < .001; hazard ratio, 0.444; 95% CI, 0.331 to 0.595; P < .001). The most common grade 3 to 4 nonhematologic adverse events were hand-foot syndrome, proteinuria, and hypertension. Conclusion: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10
Ferlay, J. (2010) · Medical Entomology and Zoology · Cited by 1,633
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Self-citationKang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4585 · Cited by 660
Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., Sun, G., Yang, Y., Wang, L., Xu, N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8585 · Cited by 533
Self-citation
Cited by
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Self-citationExploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Gastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Self-citationWang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · Cancer Communications · doi:10.1186/s40880-019-0349-9 · Cited by 810
Self-citationWang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12193 · Cited by 624
Self-citationClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604
Self-citationAjani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594
Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H.-T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30739-3 · Cited by 511
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2024) · Cancer Communications · doi:10.1002/cac2.12516 · Cited by 428
Self-citationSundar, R., Nakayama, I., Markar, S. R., Shitara, K., van Laarhoven, H. W. M., Janjigian, Y. Y., & Smyth, E. C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00052-2 · Cited by 393
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of Gastric Cancer · doi:10.5230/jgc.2019.19.e8 · Cited by 392
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Self-citationSignaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 320
Self-citationTargeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 298
Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., Ng, M., Chen, L. T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy498 · Cited by 289
Self-citationTargeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Liu, K., Ren, T., Huang, Y., Sun, K., Bao, X., Wang, S., Zheng, B., & Guo, W. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.422 · Cited by 264
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35431-x · Cited by 253
Self-citationFan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
Self-citationXie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0542 · Cited by 128
Self-citationZheng, G.-L., Zhang, G.-J., Zhao, Y., & Zheng, Z.-C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901182 · Cited by 15
Meade, A., Santero, M., Savall-Esteve, O., Bracchiglione, J., Leache, L., Selva, A., Macias, I., Cerdà, P., & Bonfill Cosp, X. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01155-y · Cited by 1
Metadata
- Authors
- Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., Wang, Z., Wang, Q., Ouyang, X., Yang, Y., Ba, Y., Liang, J., Lin, X., Luo, D., Zheng, R., Wang, X., Sun, G., Wang, L., Zheng, L., Guo, H., Wu, J., Xu, N., Yang, J., Zhang, H., Cheng, Y., Wang, N., Chen, L., Fan, Z., Sun, P., & Yu, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-01
- Volume
- 34
- Issue
- 13
- Pages
- 1448-1454
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2276228008
- Cited by
- 972
- References
- 19
- FWCI
- 95.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.